Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Study ID
NCT05965141
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Aribulin;carboplatin;bevacizumab — DRUG
    Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.

Study Details

This is a prospective phase II, single-center, single-arm clinical study of platinum-sensitive relapsed ovarian cancer. The main objective of this study is to evaluate the efficacy, safety and tolerability of Aribrine combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive relapsed ovarian cancer.

Key Dates

Start date
Aug 1, 2023
Status verified
Apr 2023
Primary completion
Apr 1, 2025
Completion
Jun 1, 2025

Study Design

Enrollment
38 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aribulin in combination with carboplatin and bevacizumab
    This is a one-arm study without randomization. There was only one trial group of Aribulin combined with carboplatin and bevacizumab.

Primary Outcome Measure

Objective response rate [ Time Frame: During treatment, imaging examinations were performed ±3 days every 2 cycles and D0±1 days per cycle for CA-125. When the efficacy was evaluated as PR or CR, imaging was performed again at 6 weeks ±3 days. ]

Central Contacts

Related Studies